ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Prime Medicine Inc

Prime Medicine Inc (PRME)

3.20
0.23
(7.74%)
Closed November 23 4:00PM
3.26
0.06
(1.88%)
After Hours: 6:53PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.060.100.040.08-0.02-33.33 %1019511/22/2024

Professional-Grade Tools, for Individual Investors.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.001.702.200.951.950.000.00 %02-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PDYNPalladyne AI Corporation
$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
$ 8.26
(89.02%)
2.03M
XCURExicure Inc
$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
$ 6.21
(-54.07%)
897.51k
CETXCemtrex Inc
$ 0.1146
(-41.74%)
22.89M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
$ 3.09
(-26.25%)
305.85k
ENSCEnsysce Biosciences Inc
$ 0.4414
(-25.49%)
3.93M
ELABElevai Labs Inc
$ 0.0201
(-0.50%)
415.87M
NVDANVIDIA Corporation
$ 141.95
(-3.22%)
229.93M
SMCISuper Micro Computer Inc
$ 33.15
(11.62%)
155.43M
VRPXVirpax Pharmaceuticals Inc
$ 0.5501
(-6.72%)
154.17M
SOUNSoundHound AI Inc
$ 8.24
(18.05%)
103.6M

PRME Discussion

View Posts
Monksdream Monksdream 1 month ago
PRME under $5
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
PRME new 52 week low
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 months ago
PRME: Glad I grabbed a chunk of THIS ONE!!!!
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 2 months ago
"Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones,..."

"On the Effective Date, the Company entered into the Purchase Agreement with BMS, pursuant to which the Company agreed to issue and sell, and BMS agreed to purchase, in an unregistered offering (the β€œOffering”), 11,006,163 shares [...] for an aggregate purchase price of $55.0 million..."
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
PRME new 52=week low
πŸ‘οΈ0
wiwineguy wiwineguy 3 months ago
K. I'm in!
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
DAKT
πŸ‘οΈ0
wiwineguy wiwineguy 3 months ago
You are amazing Monk. Any recommendations
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
PRME under $5
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
PRME new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
PRME under $6
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
PRME under $10:
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
PRME under $10
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
πŸ‘οΈ0
NY1972 NY1972 7 months ago
This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
πŸ‘οΈ0
jondoeuk jondoeuk 9 months ago
The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock